Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (282 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

282 publications

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 282 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )
Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )
Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )
Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )
Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )
Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )
Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )
J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )
Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )
Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )
J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	NFjpPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLOTWM2OD1yLkC2NUDPxE1?	NH36[2tUSU6JRWK=
ALL-PO	NGG5OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT5c5dtUUN3ME2wMlA3OzV3IN88US=>	MmjlV2FPT0WU
697	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7wR\|dnUUN3ME2wMlA6QTd4IN88US=>	NGfjO49USU6JRWK=
NCI-H748	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMUCzN\|Qh\|ryP	NY\PRoZtW0GQR1XS
NKM-1	M3r0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMUC5NVIh\|ryP	NXTPbXNYW0GQR1XS
ES1	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYru[4lPUUN3ME2wMlEyOjV3IN88US=>	NGCxcnNUSU6JRWK=
NCI-H1963	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMUG1O\|kh\|ryP	NWPHXopPW0GQR1XS
NCI-H1417	NV3xPFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;xTWM2OD1yLkGyPVc1KM7:TR?=	NE\jS3ZUSU6JRWK=
NEC8	NUS3R5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jpT2lEPTB;MD6xN\|UzPyEQvF2=	NX[3[2ZiW0GQR1XS
CRO-AP2	M{H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPlPFF6UUN3ME2wMlE3QDh7IN88US=>	MXXTRW5ITVJ?
A3-KAW	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nmbmlEPTB;MD6xO\|YzPyEQvF2=	MX3TRW5ITVJ?
SF539	M1HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXE[FhKSzVyPUCuNVk2QTNizszN	NH;sbGFUSU6JRWK=
NOS-1	M{jNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPUPGFKSzVyPUCuNVk3OTlizszN	NHXXeVhUSU6JRWK=
NTERA-S-cl-D1	M4L6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMkCxNVMh\|ryP	MUTTRW5ITVJ?
COR-L88	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjKcXRXUUN3ME2wMlIzQTV7IN88US=>	Mn3LV2FPT0WU
EM-2	NVTRSIVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPQUlJXUUN3ME2wMlI1ODd7IN88US=>	M1v0PXNCVkeHUh?=
KARPAS-45	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfYSnJKUUN3ME2wMlI4QDN\|IN88US=>	MXzTRW5ITVJ?
DSH1	NI\KR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMki3NFgh\|ryP	NVfpR3JWW0GQR1XS
HT-144	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPpcVhKSzVyPUCuN\|AzPTZizszN	M2fYT3NCVkeHUh?=
ATN-1	NVfIcZZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTnTWM2OD1yLkOwOVc3KM7:TR?=	MVHTRW5ITVJ?
HEL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwM{GzOFgh\|ryP	NWjmb3AyW0GQR1XS
NB12	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{m5UmlEPTB;MD6zNVc2PiEQvF2=	M3npXXNCVkeHUh?=
LU-139	NHzyS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrZS\|lKSzVyPUCuN\|M2OSEQvF2=	MoDqV2FPT0WU
J-RT3-T3-5	NH\ZcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHoNIVKUUN3ME2wMlM{PzF4IN88US=>	MoDCV2FPT0WU
MOLT-13	M3X1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ewSWlEPTB;MD6zN\|gyKM7:TR?=	NGjt[4ZUSU6JRWK=
SR	NF20fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLxdWxKSzVyPUCuN\|QzPjFizszN	M1T4bnNCVkeHUh?=
CMK	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\4bXpPUUN3ME2wMlM2PzJ5IN88US=>	NYHGTohsW0GQR1XS
ES8	NHjROIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3DNYN1UUN3ME2wMlM3ODJ{IN88US=>	MnjCV2FPT0WU
LB647-SCLC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\HTWM2OD1yLkO2O\|Mh\|ryP	NXvjV\|BFW0GQR1XS
TE-8	NGjtW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37HNGlEPTB;MD6zOlk{PSEQvF2=	NHTkR2NUSU6JRWK=
BV-173	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwM{exNlEh\|ryP	M{\sfHNCVkeHUh?=
DEL	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPJVYpVUUN3ME2wMlM4PDh5IN88US=>	NEe2Xo9USU6JRWK=
ARH-77	M1HHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TGWGlEPTB;MD6zPFE6OyEQvF2=	Mlq1V2FPT0WU
NCCIT	NWm2NIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfveZhsUUN3ME2wMlM5PjR7IN88US=>	M3ftbnNCVkeHUh?=
RPMI-8402	NUfxbJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS1TJR{UUN3ME2wMlM5PzBzIN88US=>	M3vlOnNCVkeHUh?=
MONO-MAC-6	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXqTWM2OD1yLkO4O\|c3KM7:TR?=	NYjqSodxW0GQR1XS
SK-MM-2	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrhUIN1UUN3ME2wMlM6QDZ6IN88US=>	NIr0NI1USU6JRWK=
CHP-126	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwNECyN\|Eh\|ryP	Mof3V2FPT0WU
A101D	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwNECzJO69VQ>?	NVXXT\|RIW0GQR1XS
SCH	NE\XTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj6VlhXUUN3ME2wMlQxOzR{IN88US=>	MWrTRW5ITVJ?
NMC-G1	M1q5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXFToxKSzVyPUCuOFA{PjdizszN	NY\4d2NvW0GQR1XS
NCI-H209	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDYV4RKSzVyPUCuOFA3OTNizszN	MkjVV2FPT0WU
MOLT-16	NYfyVGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jsTGlEPTB;MD60NVAyPyEQvF2=	MUTTRW5ITVJ?
RPMI-6666	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2WzXWlEPTB;MD60NVEzKM7:TR?=	Mme2V2FPT0WU
OPM-2	M4jvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVu0S\|N2UUN3ME2wMlQyPTF\|IN88US=>	NWe5U2RPW0GQR1XS
MRK-nu-1	M{HUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwNEOxOVMh\|ryP	NWnKb41sW0GQR1XS
BC-1	NFvlZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TpbWlEPTB;MD60N\|QxOyEQvF2=	NETzdmpUSU6JRWK=
MHH-NB-11	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXm0dJpXUUN3ME2wMlQ{PDV\|IN88US=>	MU\TRW5ITVJ?
Ramos-2G6-4C10	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK2eVl5UUN3ME2wMlQ{QDl5IN88US=>	NHn1SGhUSU6JRWK=
LS-513	M2DKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnnTWM2OD1yLkS0OVAyKM7:TR?=	M2nqS3NCVkeHUh?=
K5	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVywR\|hSUUN3ME2wMlQ4ODJ3IN88US=>	NVrZdGRHW0GQR1XS
HOP-62	NGXHZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrDb2dOUUN3ME2wMlQ5OzV6IN88US=>	NI\yNWNUSU6JRWK=
NCI-H187	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j3WWlEPTB;MD60PVIzPyEQvF2=	NV3sSmJxW0GQR1XS
BE-13	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfMTWM2OD1yLkS5OlYyKM7:TR?=	MmH0V2FPT0WU
HC-1	M3zYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4O2SGlEPTB;MD61NFQ4OyEQvF2=	MnPkV2FPT0WU
ACN	M2PPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\x[5BQUUN3ME2wMlUyODJ6IN88US=>	Mn7lV2FPT0WU
HCC1599	NWnrS2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTDbIxOUUN3ME2wMlUyPTdizszN	NUHqcGJ7W0GQR1XS
MV-4-11	M3fJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHqcnluUUN3ME2wMlU{ODRzIN88US=>	MUnTRW5ITVJ?
LC-2-ad	M2LHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjVblFWUUN3ME2wMlU{PjZ\|IN88US=>	Mn;vV2FPT0WU
HL-60	NWXncolvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwNUSyOlEh\|ryP	MWTTRW5ITVJ?
NB17	M1TL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwNUSzPEDPxE1?	NYnMWXlnW0GQR1XS
TE-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPNTWM2OD1yLkW1N\|A3KM7:TR?=	M4X0UXNCVkeHUh?=
NCI-H524	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnoPFNvUUN3ME2wMlU2PDBzIN88US=>	M3OwUHNCVkeHUh?=
MZ7-mel	NIezWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfXXGVKSzVyPUCuOVYyODVizszN	NX35WW9WW0GQR1XS
L-363	NWD0NVk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13BR2lEPTB;MD61OlY2PyEQvF2=	MonEV2FPT0WU
BL-41	NVXmW2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzoPFM6UUN3ME2wMlU3QDh7IN88US=>	MkfZV2FPT0WU
LU-134-A	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\xeoljUUN3ME2wMlU4ODd\|IN88US=>	MlvZV2FPT0WU
SIG-M5	MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvsTWM2OD1yLkW3PFQ5KM7:TR?=	MlrnV2FPT0WU
ONS-76	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX3TWM2OD1yLkW4NlQzKM7:TR?=	NWnOUYxoW0GQR1XS
KARPAS-299	NUixPJFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwNUi1NFQh\|ryP	NGL1[2FUSU6JRWK=
DU-4475	NFv1OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P4[mlEPTB;MD61PFcxOyEQvF2=	NWHZNpVEW0GQR1XS
NB69	NWixfmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrVSWZ[UUN3ME2wMlU6QDJ3IN88US=>	MkLhV2FPT0WU
MHH-PREB-1	NVXIblJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jyTWlEPTB;MD62NFcyQSEQvF2=	NHLOPW1USU6JRWK=
LU-165	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\ZSmlEPTB;MD62NVgyOiEQvF2=	NFKweFJUSU6JRWK=
LOUCY	NX7ufGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwNkOzOlQh\|ryP	M2ryPXNCVkeHUh?=
NCI-H526	NXTzeYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nCTGlEPTB;MD62N\|U1OSEQvF2=	MVzTRW5ITVJ?
KE-37	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HIU2lEPTB;MD62OFI4PiEQvF2=	MojhV2FPT0WU
NALM-6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfFTWM2OD1yLk[0PFYh\|ryP	MYfTRW5ITVJ?
CW-2	NHvqU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwNkW3PVQh\|ryP	NHTpW4lUSU6JRWK=
SU-DHL-1	NV3GTZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNkW5OFch\|ryP	NW\ST4dKW0GQR1XS
NB13	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTHTWM2OD1yLk[2PFE4KM7:TR?=	M4H0fnNCVkeHUh?=
QIMR-WIL	M4DyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zRS2lEPTB;MD62PFM1OyEQvF2=	M3j3R3NCVkeHUh?=
ECC12	M1\R[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwN{CwPFYh\|ryP	NHrKV5hUSU6JRWK=
KALS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;xelAxUUN3ME2wMlcxPDl{IN88US=>	MX7TRW5ITVJ?
COR-L279	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXacYNKSzVyPUCuO\|A6QTZizszN	NI\s[5ZUSU6JRWK=
NB14	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL2TWM2OD1yLkeyOlE4KM7:TR?=	M2P3NHNCVkeHUh?=
CCRF-CEM	NX71eIRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7pVmhkUUN3ME2wMlc1PjZzIN88US=>	NF;W[41USU6JRWK=
SW954	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwN{W5PVkh\|ryP	MVfTRW5ITVJ?
IST-SL1	M3X0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwN{ezOFgh\|ryP	M3fUWXNCVkeHUh?=
LAMA-84	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfOTWM2OD1yLke3OVY4KM7:TR?=	MUXTRW5ITVJ?
Daudi	NVPMRYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrmRVl4UUN3ME2wMlc4PjhzIN88US=>	MX;TRW5ITVJ?
BC-3	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHJNXJKSzVyPUCuO\|g{ODhizszN	M3zv[XNCVkeHUh?=
HCC2998	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\UemlEPTB;MD63PFM3KM7:TR?=	NUmzdWFIW0GQR1XS
NCI-H69	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEO1V3FKSzVyPUCuPFAyPDdizszN	NIPjNpJUSU6JRWK=
CPC-N	M2TyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnDU2hKSzVyPUCuPFA2OjRizszN	MVPTRW5ITVJ?
NOMO-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwOEGwPFQh\|ryP	NX\KeHlHW0GQR1XS
CESS	Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTkTWM2OD1yLkixNVk4KM7:TR?=	M3;IfHNCVkeHUh?=
LC4-1	NXjFO4I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17hTmlEPTB;MD64OFAxPyEQvF2=	M3;HfHNCVkeHUh?=
BL-70	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\W[ZRKSzVyPUCuPFU4ODJizszN	NEe0[m9USU6JRWK=
ES4	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDnTWM2OD1yLki1PFY5KM7:TR?=	Ml3uV2FPT0WU
HCE-T	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzqZYtKSzVyPUCuPFcyPzFizszN	M{D6NHNCVkeHUh?=
JAR	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEj1N4FKSzVyPUCuPFc5OjdizszN	M{\mW3NCVkeHUh?=
ST486	NHvWPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzkd3doUUN3ME2wMlg4QTF5IN88US=>	NUmx[pFpW0GQR1XS
KS-1	NFzXUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO2TmRKSzVyPUCuPFgxQTZizszN	MkjXV2FPT0WU
GDM-1	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHGN5pmUUN3ME2wMlg5Pjh5IN88US=>	NI\GbIVUSU6JRWK=
EHEB	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEn5cYVKSzVyPUCuPVI2QDVizszN	MknlV2FPT0WU
LB2518-MEL	M4LmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvDPVd1UUN3ME2wMlk{Ojh2IN88US=>	NYrycW4{W0GQR1XS
GOTO	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPjXo0{UUN3ME2wMlk2ODd4IN88US=>	MmqyV2FPT0WU
LXF-289	M{XyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M160eGlEPTB;MD65OVkxOSEQvF2=	NGjOOoJUSU6JRWK=
ES6	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\0[pRKSzVyPUCuPVY1OzdizszN	NXTxenQ2W0GQR1XS
OS-RC-2	NYnQRos6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwOU[4N{DPxE1?	NY\veY1VW0GQR1XS
DMS-153	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\CV2lEPTB;MD65O\|Q3QSEQvF2=	M4\KVXNCVkeHUh?=
SK-PN-DW	NUjDc5Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7xNVdKUUN3ME2wMlk4QDNzIN88US=>	NVXZS3hyW0GQR1XS
HH	NImwdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvOR\|lKSzVyPUCuPVg6PTlizszN	MV\TRW5ITVJ?
SH-4	NF21SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVK4S4htUUN3ME2xMlAzPDFizszN	NEDjcVlUSU6JRWK=
MOLT-4	M{LUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf0SZRXUUN3ME2xMlA{PDV2IN88US=>	MofuV2FPT0WU
TGW	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTFwMEe2O\|Uh\|ryP	MVTTRW5ITVJ?
L-540	NH36UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSxTWM2OD1zLkGwOlA1KM7:TR?=	NF3RN2JUSU6JRWK=
PF-382	M2O2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknFTWM2OD1zLkGxOVE{KM7:TR?=	NELUZ2JUSU6JRWK=
LC-1F	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV24[pd1UUN3ME2xMlEzODB5IN88US=>	NWnHfWNLW0GQR1XS
OVCAR-4	M3y4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfVUWpKSzVyPUGuNVMyPjVizszN	NHjWW3NUSU6JRWK=
A4-Fuk	NXXSZ4FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFwMUWzOlQh\|ryP	MV\TRW5ITVJ?
HCC2218	M2PFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\mN2lEPTB;MT6xOlY1OSEQvF2=	M3rUVHNCVkeHUh?=
HAL-01	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTFwMU[5OFMh\|ryP	NXzjTWJUW0GQR1XS
IST-MEL1	M2XYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGraSmdKSzVyPUGuNVc3PTlizszN	MmnCV2FPT0WU
NCI-H719	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnQTWM2OD1zLkG3PFk5KM7:TR?=	MojUV2FPT0WU
EVSA-T	NWLLOoZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjrbWJyUUN3ME2xMlE5OTF2IN88US=>	MkDQV2FPT0WU
SK-NEP-1	M3TzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHEeYxKSzVyPUGuNlAzPjZizszN	MWXTRW5ITVJ?
OCUB-M	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDQWJU5UUN3ME2xMlIyPDh7IN88US=>	NGrHR\|dUSU6JRWK=
MEG-01	M{fRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\acVJKSzVyPUGuNlIyOThizszN	NF\wOpZUSU6JRWK=
no-10	M1jxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H6V2lEPTB;MT6yN\|EyOiEQvF2=	M{DsTnNCVkeHUh?=
MHH-CALL-2	NVzYUXlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj2e3RqUUN3ME2xMlI1PzJzIN88US=>	M3Pw[HNCVkeHUh?=
SK-N-DZ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe0OZdKSzVyPUGuNlQ4PzZizszN	M1LLUHNCVkeHUh?=
SCLC-21H	NXjrOFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXyR3VKSzVyPUGuNlY1PzhizszN	NHvKUHBUSU6JRWK=
CTV-1	NXvMTXhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLvTWM2OD1zLkK3OFI2KM7:TR?=	NEDj[pFUSU6JRWK=
NB1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjOVFRKSzVyPUGuNlc4OzJizszN	M4LkN3NCVkeHUh?=
NCI-H64	M4LGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTFwMki0OlIh\|ryP	MULTRW5ITVJ?
MDA-MB-134-VI	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTGTWM2OD1zLkK4OVc4KM7:TR?=	NEnsdJdUSU6JRWK=
LB2241-RCC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rTUWlEPTB;MT6yPFY3OyEQvF2=	NHTZc5JUSU6JRWK=
8-MG-BA	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Xk[mlEPTB;MT6yPFg3PiEQvF2=	NGLhPJFUSU6JRWK=
LP-1	NYTRV2ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO3SohKSzVyPUGuNlk6PDdizszN	MUTTRW5ITVJ?
LS-411N	M1j4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET1bFhKSzVyPUGuN\|A6QThizszN	NUHQPIpGW0GQR1XS
CAL-148	M4L0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTFwM{K1OFIh\|ryP	MXzTRW5ITVJ?
NCI-H2171	NWfzdml6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHxTWM2OD1zLkO0OVAzKM7:TR?=	MU\TRW5ITVJ?
JiyoyeP-2003	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILDXodKSzVyPUGuN\|U{QSEQvF2=	MnLOV2FPT0WU
NCI-H2107	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXaeXZoUUN3ME2xMlM2QDh\|IN88US=>	NE\vZmpUSU6JRWK=
BB30-HNC	NU\iUHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYThXWZbUUN3ME2xMlM5QTd6IN88US=>	NFr6TGpUSU6JRWK=
K-562	NGrIS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwM{myNVkh\|ryP	NWfnb2FWW0GQR1XS
PSN1	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnaTWM2OD1zLkSyNlg4KM7:TR?=	MnzCV2FPT0WU
HCC2157	NIDVOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTFwNEK2PVEh\|ryP	MXLTRW5ITVJ?
SBC-1	NGfhW\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2W1T2lEPTB;MT60Nlc1OSEQvF2=	NH7vSnVUSU6JRWK=
MC116	NYHKWnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrRdG9lUUN3ME2xMlQ{PjF3IN88US=>	MUPTRW5ITVJ?
KARPAS-422	NGLxZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fUR2lEPTB;MT60OVM2QCEQvF2=	M{e5VHNCVkeHUh?=
LB996-RCC	NU\mc5Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PROmlEPTB;MT60O\|ExOyEQvF2=	MYnTRW5ITVJ?
MSTO-211H	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPNTWM2OD1zLkS3PVg4KM7:TR?=	M3THVHNCVkeHUh?=
BT-474	NX;oOllpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGT3e3NKSzVyPUGuOVE4PjRizszN	M4rTXnNCVkeHUh?=
A388	M{\aTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDHd2l5UUN3ME2xMlUyQTR3IN88US=>	NGXYVmFUSU6JRWK=
SJSA-1	NGXIOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jhUGlEPTB;MT61NlI3KM7:TR?=	MnPOV2FPT0WU
COLO-829	NX;MNmxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlT0TWM2OD1zLkWzOVY1KM7:TR?=	MmTUV2FPT0WU
KM-H2	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF24cIZKSzVyPUGuOVY3PyEQvF2=	MUTTRW5ITVJ?
GR-ST	M4nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PZXGlEPTB;MT61OlgzKM7:TR?=	M4n1SnNCVkeHUh?=
RPMI-8866	NVnJSIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PqUmlEPTB;MT62NFE1PCEQvF2=	NHPnVpBUSU6JRWK=
KG-1	MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O1[WlEPTB;MT62NVkxOSEQvF2=	NX;FVnhSW0GQR1XS
NCI-H82	NYT4WHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rEeGlEPTB;MT62N\|QxPiEQvF2=	M2rXXHNCVkeHUh?=
LB1047-RCC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zPPGlEPTB;MT62N\|Q2QSEQvF2=	MX7TRW5ITVJ?
KM12	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\WZ2lEPTB;MT62OFch\|ryP	MWTTRW5ITVJ?
NB5	NX73NVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjOWI5oUUN3ME2xMlY2Pjd5IN88US=>	Mkj0V2FPT0WU
HDLM-2	M2LBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DJWWlEPTB;MT62PFI5OSEQvF2=	Mk[5V2FPT0WU
KU812	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLTR5lKSzVyPUGuOlk3ODVizszN	M{HWS3NCVkeHUh?=
DB	NFXOZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXyUWpKSzVyPUGuO\|A{PTNizszN	MV7TRW5ITVJ?
HD-MY-Z	M3f5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjXRpcyUUN3ME2xMlc2OjN2IN88US=>	MlP3V2FPT0WU
KURAMOCHI	NX3XSHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLhV2xKSzVyPUGuO\|czODdizszN	M4HUcXNCVkeHUh?=
ETK-1	NIC5UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrOOGRSUUN3ME2xMlc5QDd7IN88US=>	MmHNV2FPT0WU
SK-UT-1	NHjyPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnvelFtUUN3ME2xMlc6Ozh6IN88US=>	NWraTGk3W0GQR1XS
HUTU-80	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwN{m1NFgh\|ryP	M4q5R3NCVkeHUh?=
ES7	NWXPWWVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXjenJKSzVyPUGuPFA{ODJizszN	M3vqfHNCVkeHUh?=
SW872	NED0OYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jWeWlEPTB;MT64NVM6PSEQvF2=	MoDVV2FPT0WU
TK10	M3O3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\Pc2lEPTB;MT64N\|ExQCEQvF2=	MWrTRW5ITVJ?
LB831-BLC	NID2b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWm5fldIUUN3ME2xMlg{PTZ\|IN88US=>	NVrsPWJWW0GQR1XS
TE-9	NED0NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzGOoxKSzVyPUGuPFQ1OjJizszN	M2PBNnNCVkeHUh?=
MLMA	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLITWM2OD1zLki4NlM1KM7:TR?=	NIfL[2hUSU6JRWK=
D-542MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnFT2RKSzVyPUGuPFk{PzNizszN	MonTV2FPT0WU
EW-16	NEPSdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{THfGlEPTB;MT65NlczKM7:TR?=	M4exbXNCVkeHUh?=
LOXIMVI	NGHubIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHi0cm1KSzVyPUGuPVMzQCEQvF2=	NIj2fYdUSU6JRWK=
GB-1	NIT3XWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPVUm1KSzVyPUGuPVM5PjZizszN	NY\SOFNpW0GQR1XS
IST-SL2	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ezeGlEPTB;Mj6wNFI3OiEQvF2=	NXLSRlAxW0GQR1XS
LAN-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;mUWlEPTB;Mj6wNVk3PiEQvF2=	NVL1[nVWW0GQR1XS
NCI-H510A	NVjTPHROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLOZ21FUUN3ME2yMlA1PTB{IN88US=>	NG[0UodUSU6JRWK=
NCI-H1092	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1P3dWlEPTB;Mj6wOVEzPCEQvF2=	NHrnU4xUSU6JRWK=
HT	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj6[pZ3UUN3ME2yMlExPDV2IN88US=>	MnjkV2FPT0WU
RL95-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPtR2hIUUN3ME2yMlEyPDh{IN88US=>	MVjTRW5ITVJ?
NCI-H1355	MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHIb5FuUUN3ME2yMlEyPzl{IN88US=>	M2e1N3NCVkeHUh?=
NCI-H720	M1Twbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3WVlNTUUN3ME2yMlE3QDd\|IN88US=>	NEnCOZhUSU6JRWK=
NCI-H1522	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvN[lFKSzVyPUKuNlE4OjNizszN	MWTTRW5ITVJ?
LB373-MEL-D	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;QOHZxUUN3ME2yMlI3QTB{IN88US=>	MlzkV2FPT0WU
DG-75	NX;aXVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHBXYVbUUN3ME2yMlI4OTR6IN88US=>	NV3JR2Z4W0GQR1XS
ML-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7XTWM2OD1{LkOyPFU2KM7:TR?=	NHP5PVdUSU6JRWK=
SF126	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTpeVFKUUN3ME2yMlM{ODl2IN88US=>	M2DIdnNCVkeHUh?=
MPP-89	NEPKV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nGPGlEPTB;Mj6zN\|E1PSEQvF2=	M{W3bHNCVkeHUh?=
NCI-H345	M3XNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLkUXdKSzVyPUKuN\|MzPzdizszN	M1TBcXNCVkeHUh?=
LS-123	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jqN2lEPTB;Mj6zOFk{PiEQvF2=	NF;ZWlRUSU6JRWK=
NB10	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7L[HVKSzVyPUKuOFExQTJizszN	M4XGV3NCVkeHUh?=
CGTH-W-1	M1TmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXFfG02UUN3ME2yMlQzOjZ5IN88US=>	NUnHcYk{W0GQR1XS
CP66-MEL	NF;1NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XpSWlEPTB;Mj60O\|c4KM7:TR?=	NUXhT21rW0GQR1XS
L-428	NV7SUpRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTDZW57UUN3ME2yMlQ5PTJzIN88US=>	NIS1Z3JUSU6JRWK=
DMS-79	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jlVGlEPTB;Mj61OFExOyEQvF2=	NHTtOG1USU6JRWK=
NCI-H1882	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTJwNke1OlIh\|ryP	MmXKV2FPT0WU
KGN	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPU[VMzUUN3ME2yMlc3QDd4IN88US=>	NHzieI5USU6JRWK=
EW-1	NGXXW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fHU2lEPTB;Mj63O\|A5OyEQvF2=	MWfTRW5ITVJ?
U-266	NU\6PIl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLiSYhKSzVyPUKuPFQ5OjNizszN	MWPTRW5ITVJ?
COLO-320-HSR	M4H4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIj5[VFKSzVyPUKuPFU3PDFizszN	M2jycHNCVkeHUh?=
KMOE-2	NWfxWlY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTJwOEe3NVEh\|ryP	NYDYUJJUW0GQR1XS
BB49-HNC	NHn1Xm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmP5TWM2OD1{LkmyOFgh\|ryP	Mo\NV2FPT0WU
GI-1	M3;qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPYWmZwUUN3ME2yMlkzQTV5IN88US=>	NXPTVGFYW0GQR1XS
NCI-H1304	NHHM[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnWTWM2OD1\|LkCwOVEyKM7:TR?=	NX;IRW9DW0GQR1XS
NCI-H2227	NFvqdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fRbGlEPTB;Mz6wNlA4QSEQvF2=	Ml3pV2FPT0WU
U-87-MG	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\lZ\|BDUUN3ME2zMlA{PTF\|IN88US=>	MVPTRW5ITVJ?
NCI-H747	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXhU41KSzVyPUOuNFUzODZizszN	M4[0WHNCVkeHUh?=
CTB-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTNwMEWzO\|Yh\|ryP	MUjTRW5ITVJ?
RPMI-8226	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{KzTmlEPTB;Mz6xOFM4QCEQvF2=	Mle5V2FPT0WU
NCI-H2141	NHryN\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;aXJhwUUN3ME2zMlE3PTZ4IN88US=>	MXLTRW5ITVJ?
IST-MES1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrt[\|ZKSzVyPUOuNVgzPzlizszN	MUjTRW5ITVJ?
TE-5	NUP6TppTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTNwMkGzOFIh\|ryP	M2P3VnNCVkeHUh?=
UACC-257	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n5dWlEPTB;Mz60N\|Y2QSEQvF2=	M1;FVHNCVkeHUh?=
SK-N-FI	NFHjUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q2O2lEPTB;Mz60OVIzPyEQvF2=	NEDPOGxUSU6JRWK=
MFH-ino	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC3TWM2OD1\|LkS2OVg6KM7:TR?=	NHPOXZlUSU6JRWK=
SF268	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnVOWtlUUN3ME2zMlQ5OTd2IN88US=>	MXLTRW5ITVJ?
TE-12	NFvDeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfZeYltUUN3ME2zMlUyPjl7IN88US=>	MnzsV2FPT0WU
NB6	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\kNmlEPTB;Mz61OVU3OyEQvF2=	NVfySYVMW0GQR1XS
DJM-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnwXJFKSzVyPUOuOVk5QTlizszN	MkPzV2FPT0WU
MZ1-PC	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTNwNkG2NlQh\|ryP	NFXXRW5USU6JRWK=
OCI-AML2	NWDsS4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnlc5lKSzVyPUOuOlI3PzFizszN	NHvWeVBUSU6JRWK=
NCI-H1155	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrpUWR{UUN3ME2zMlcxQTR5IN88US=>	M1XlTXNCVkeHUh?=
RKO	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXNdYhsUUN3ME2zMlc4OTh7IN88US=>	M2OwdnNCVkeHUh?=
ECC4	NYjaSoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDJdmk5UUN3ME2zMlk4OTl3IN88US=>	M4XqPXNCVkeHUh?=
BB65-RCC	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvETWM2OD1\|Lkm3OVQ4KM7:TR?=	MoHBV2FPT0WU
EB-3	NInCeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;XTWM2OD1\|Lkm5OlM{KM7:TR?=	MoXQV2FPT0WU
SHP-77	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPxSGpKSzVyPUSuNFA2OjRizszN	NV;4XmxWW0GQR1XS
NCI-H2196	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3xTWM2OD12LkC1OlI2KM7:TR?=	MlK3V2FPT0WU
GI-ME-N	NYTnSo53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXq0[pZVUUN3ME20MlA3Ozl7IN88US=>	NWm3XIxXW0GQR1XS
MN-60	NHLKVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\TPWcxUUN3ME20MlExQDdizszN	MWPTRW5ITVJ?
NCI-H1694	NH;5b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTRwMUO0NFUh\|ryP	NGjrU4pUSU6JRWK=
LU-65	NH3rU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLlTWM2OD12LkG1N\|MzKM7:TR?=	Ml7yV2FPT0WU
NCI-H1436	NGfoO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfNTWM2OD12LkG4N\|M{KM7:TR?=	MXrTRW5ITVJ?
KINGS-1	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHF[ZdtUUN3ME20MlMyPDN{IN88US=>	MUDTRW5ITVJ?
GT3TKB	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfDTWM2OD12LkOzNlY5KM7:TR?=	M3rERnNCVkeHUh?=
Becker	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\0e2NKSzVyPUSuN\|c{OTJizszN	MUnTRW5ITVJ?
HCC1187	M4DNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTRwOEm2OVch\|ryP	M3radHNCVkeHUh?=
D-502MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjFTWM2OD13LkCwOFE3KM7:TR?=	MnnUV2FPT0WU
VA-ES-BJ	NFvtPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTVwMUO3O\|gh\|ryP	M33qSXNCVkeHUh?=
NB7	M2n1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVWwWJVIUUN3ME21MlE1OTF{IN88US=>	NU\SenJYW0GQR1XS
SW962	NGjKdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTVwM{i4NVQh\|ryP	M2fsfnNCVkeHUh?=
no-11	NGfyTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvtSHdKSzVyPUWuO\|Y{PDNizszN	M{C2TnNCVkeHUh?=
KNS-81-FD	NX3CeoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfiTWM2OD13LkmwOlk1KM7:TR?=	NV[3WYpyW0GQR1XS
COLO-684	NX;YN493T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq5TWM2OD13Lkm5OFk1KM7:TR?=	M4fGenNCVkeHUh?=
D-263MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr2cHNKSzVyPU[uNFg5QTVizszN	M4HzXnNCVkeHUh?=
EW-24	NX7QNYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULYOJFLUUN3ME22MlI5PTFizszN	MlW0V2FPT0WU
TE-10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTZwNEK2NlMh\|ryP	M{izTXNCVkeHUh?=
EKVX	M4K0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTZwNE[zNlEh\|ryP	MkDQV2FPT0WU
NCI-H1648	NHTDdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTZwNke1OVch\|ryP	M4LUR3NCVkeHUh?=
LB771-HNC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTlTWM2OD14LkmyN\|AyKM7:TR?=	MlOxV2FPT0WU
SK-MEL-1	NHn2VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRThwMUOxOlYh\|ryP	MXLTRW5ITVJ?
COLO-668	NFHzbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnuOoFKSzVyPUiuNlc4QDZizszN	M{\mN3NCVkeHUh?=
EW-12	NVywelhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRThwNEC4NFMh\|ryP	M2fqS3NCVkeHUh?=
A253	NFTJTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rrSmlEPTB;OD64OFY3OSEQvF2=	M1jGdXNCVkeHUh?=
NCI-H2126	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjlTWM2OD16Lki5N\|E6KM7:TR?=	NEfFUHZUSU6JRWK=
Calu-6	M3jwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRThwOUmwOFIh\|ryP	NW\FdZhCW0GQR1XS
NCI-H23	NFGzXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIe2U2FKSzVyPUmuNVc4PDZizszN	M1fHUXNCVkeHUh?=
WSU-NHL	NH;sSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPRcFRwUUN3ME25Mlc4PDd6IN88US=>	M3nPSXNCVkeHUh?=
MMAC-SF	M1\ubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjBTWM2OD17Lkm3PVA1KM7:TR?=	MXzTRW5ITVJ?
SK-LMS-1	M{mwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTFyLkK4N\|Qh\|ryP	M3;V[nNCVkeHUh?=
GCIY	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S3NGlEPTB;MUCuOVkzPCEQvF2=	NUG0VGVMW0GQR1XS
TE-15	M2ruU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHPTWM2OD1zMT62NFA1KM7:TR?=	MnvOV2FPT0WU
EoL-1-cell	M1q1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELhe2lKSzVyPUGxMlc3QDJizszN	NEjEUGZUSU6JRWK=
NCI-H2081	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTFzLke3PFYh\|ryP	MUfTRW5ITVJ?
EW-3	NIX1eoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnQTWM2OD1zMj6yOFY{KM7:TR?=	M3n3SnNCVkeHUh?=
CAS-1	NFvKfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF{LkO2N\|Eh\|ryP	Mn3XV2FPT0WU
C2BBe1	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfxTWM2OD1zMj62NVMyKM7:TR?=	M4jWWnNCVkeHUh?=
D-247MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTUTWM2OD1zMj63PVUzKM7:TR?=	NHn0OJJUSU6JRWK=
NCI-SNU-5	NEXJXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL5VpNKSzVyPUGyMlgxOTNizszN	NWfTbVB1W0GQR1XS
LS-1034	NU\pPZNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2WyO2lEPTB;MUSuN\|k4PSEQvF2=	MorDV2FPT0WU
EW-18	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXQVGVKUUN3ME2xOE41PDhizszN	NFv3[FNUSU6JRWK=
Raji	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjyTWM2OD1zND61NFQ6KM7:TR?=	NF7OV25USU6JRWK=
D-283MED	M{HQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILnTFhKSzVyPUG0MlYzPzFizszN	MoLoV2FPT0WU
MZ2-MEL	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XOWmlEPTB;MUSuPVY6PiEQvF2=	MV\TRW5ITVJ?
NCI-SNU-16	NF;RRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m3OWlEPTB;MUWuOFY{OyEQvF2=	MWDTRW5ITVJ?
P30-OHK	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDuWVdKSzVyPUG3Mlc5OzFizszN	Mn:4V2FPT0WU
RXF393	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2OxVmlEPTB;MUmuNFE5PiEQvF2=	MULTRW5ITVJ?
NCI-H1395	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnKxTWM2OD1{MD62O\|A{KM7:TR?=	MV\TRW5ITVJ?
U-698-M	NIP0e\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfZXXhKSzVyPUKwMlcxPzVizszN	NYSwW3hpW0GQR1XS
NCI-SNU-1	NEPPXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTJyLkeyNlMh\|ryP	NGDUOJZUSU6JRWK=
SW684	M4\ncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHGwS3BKSzVyPUKxMlE4OTZizszN	M17JTnNCVkeHUh?=
NCI-H716	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[1TGlEPTB;MkGuN\|E2PCEQvF2=	MnPzV2FPT0WU
JVM-2	NIPhWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzCOZVsUUN3ME2yNU41OTN\|IN88US=>	NHL0VY1USU6JRWK=
NCI-H1581	M2HmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXDVHFKSzVyPUKyMlQyPDhizszN	NFjhdI5USU6JRWK=
CA46	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G2XWlEPTB;M{GuOlk{PiEQvF2=	NFXKeXJUSU6JRWK=
SNB75	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXPTWM2OD1\|Mz62OVA{KM7:TR?=	NYi5S4w2W0GQR1XS
KNS-42	NITxVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTN3Lkm2NlQh\|ryP	M33PdnNCVkeHUh?=
TUR	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTN4LkC1NlEh\|ryP	MW\TRW5ITVJ?
REH	NX7TPXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTN5LkiyNVEh\|ryP	MWXTRW5ITVJ?
EW-22	M2Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTR{LkK4PFUh\|ryP	MkPJV2FPT0WU
NCI-H446	NEDGPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf0cm1KSzVyPUSyMlc5PTNizszN	NVH3dmV3W0GQR1XS
ES3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvMTWM2OD12Mz6xN\|M6KM7:TR?=	NFjEdY5USU6JRWK=
EW-11	NWTlOGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qxcmlEPTB;NESuPFIyQCEQvF2=	MoDiV2FPT0WU
RH-1	NGLvN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1[0b2lEPTB;NEeuOVgyOiEQvF2=	NGrZVoNUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SNDX-275
Smiles	NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Active not recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)